OM
QTTB icon

Opaleye Management’s Q32 Bio QTTB Stock Holding History

Opaleye Management’s Portfolio QTTB Stock Details QTTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.06M Buy
1,256,228
+1,042,865
+489% +$4.95M 1.06% 24
2025
Q4 		$708K Buy
+213,363
New +$603K 0.09% 50

Other funds holding QTTB

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Opaleye Management's QTTB Position: Q1 2026 in Review

Opaleye Management increased its Q32 Bio (QTTB) stake by 489% in Q1 2026, buying an estimated $4.95M and bringing the position to 1,256,228 shares worth $8.06M. The position accounts for 1.06% of the portfolio, ranked #24.

Opaleye Management first reported a position in QTTB in Q4 2025 and has held it in 2 quarters since. 54 funds tracked by Wall St. Rank hold QTTB as of Q1 2026.

  • Opaleye Management held 1,256,228 shares of Q32 Bio worth $8.06M as of Q1 2026.
  • Opaleye Management bought 1,042,865 Q32 Bio shares in Q1 2026, an estimated $4.95M.
  • Q32 Bio made up 1.06% of Opaleye Management's portfolio in Q1 2026, its #24 holding.
  • Opaleye Management first reported a position in Q32 Bio in Q4 2025 and has held it in 2 quarters since.
  • 54 funds tracked by Wall St. Rank held Q32 Bio as of Q1 2026.

Based on Opaleye Management's 13F filing for Q1 2026, filed 15 May 2026.